Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

50 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting multidrug resistance in cancer.
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Szakács G, et al. Among authors: ludwig ja. Nat Rev Drug Discov. 2006 Mar;5(3):219-34. doi: 10.1038/nrd1984. Nat Rev Drug Discov. 2006. PMID: 16518375 Review.
Defeating drug resistance in cancer.
Gottesman MM, Ludwig J, Xia D, Szakács G. Gottesman MM, et al. Discov Med. 2006 Feb;6(31):18-23. Discov Med. 2006. PMID: 17234123
Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery.
Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV. Calcagno AM, et al. Among authors: ludwig ja. Mol Pharm. 2006 Jan-Feb;3(1):87-93. doi: 10.1021/mp050090k. Mol Pharm. 2006. PMID: 16686373
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
Ludwig JA, Szakács G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MM. Ludwig JA, et al. Cancer Res. 2006 May 1;66(9):4808-15. doi: 10.1158/0008-5472.CAN-05-3322. Cancer Res. 2006. PMID: 16651436 Free PMC article.
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM. Hall MD, et al. Among authors: ludwig ja. J Med Chem. 2009 May 28;52(10):3191-204. doi: 10.1021/jm800861c. J Med Chem. 2009. PMID: 19397322 Free PMC article.
Identification of compounds selectively killing multidrug-resistant cancer cells.
Türk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM, Szakács G. Türk D, et al. Among authors: ludwig ja. Cancer Res. 2009 Nov 1;69(21):8293-301. doi: 10.1158/0008-5472.CAN-09-2422. Epub 2009 Oct 20. Cancer Res. 2009. PMID: 19843850 Free PMC article.
3D tissue-engineered model of Ewing's sarcoma.
Lamhamedi-Cherradi SE, Santoro M, Ramammoorthy V, Menegaz BA, Bartholomeusz G, Iles LR, Amin HM, Livingston JA, Mikos AG, Ludwig JA. Lamhamedi-Cherradi SE, et al. Among authors: ludwig ja. Adv Drug Deliv Rev. 2014 Dec 15;79-80:155-71. doi: 10.1016/j.addr.2014.07.012. Epub 2014 Aug 7. Adv Drug Deliv Rev. 2014. PMID: 25109853 Free PMC article. Review.
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Naing A, et al. Clin Cancer Res. 2012 May 1;18(9):2625-31. doi: 10.1158/1078-0432.CCR-12-0061. Epub 2012 Mar 31. Clin Cancer Res. 2012. PMID: 22465830 Free PMC article. Clinical Trial.
Targeted therapies for advanced Ewing sarcoma family of tumors.
Jiang Y, Ludwig J, Janku F. Jiang Y, et al. Cancer Treat Rev. 2015 May;41(5):391-400. doi: 10.1016/j.ctrv.2015.03.008. Epub 2015 Mar 27. Cancer Treat Rev. 2015. PMID: 25869102 Free PMC article. Review.
An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma.
Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Aiyer RA, Maywald RL, Buford AS, Doolittle DK, Culotta KS, O'Dorisio JE, Ludwig JA. Lamhamedi-Cherradi SE, et al. Among authors: ludwig ja. Mol Cancer Ther. 2015 Jul;14(7):1591-604. doi: 10.1158/1535-7163.MCT-14-0334. Epub 2015 May 11. Mol Cancer Ther. 2015. PMID: 25964201
50 results
Jump to page